Threshold Pharmaceuticals (THLD) has risen sharply, recording gains of 36.75% in the past 4 weeks. However, the stock has corrected -2.46% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 39.58% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 10.8% and the 50-Day Moving Average is 53.83%.The 200 Day SMA reached 109.84% Threshold Pharmaceuticals Inc. is up 197.5% in the last 3-month period. Year-to-Date the stock performance stands at 147.92%.
For the current week, the company shares have a recommendation consensus of Buy. Threshold Pharmaceuticals (NASDAQ:THLD): The stock opened at $1.13 and touched an intraday high of $1.19 on Friday. During the day, the stock corrected to an intraday low of $1.13, however, the bulls stepped in and pushed the price higher to close in the green at $1.19 with a gain of 2.59% for the day. The total traded volume for the day was 1,254,467. The stock had closed at $1.19 in the previous trading session.
Threshold Pharmaceuticals, Inc. (Threshold) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Thresholds investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Thresholds [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.